Patricia Inácio, PhD, science writer —

Life support measures, specifically the need for assisted breathing, and elevated blood levels of bilirubin, a marker of liver damage, are among the factors that predict worse outcomes after a lung transplant in people with idiopathic pulmonary arterial hypertension (IPAH), a study reports. A new predictive model that includes…

Tenax Therapeutics has been granted another U.S. patent for levosimendan, this one covering all three routes of administration and its active metabolites, for the treatment of people with PH-HFpEF, or pulmonary hypertension and heart failure with preserved ejection fraction. Issued by the U.S. Patent and Trademark Office, the…

Elevated levels of two tumor biomarkers, AFP and CA125, were found to predict disease worsening in people with idiopathic pulmonary arterial hypertension (IPAH) in a new study from China. “Changes in AFP over time serve as an indicator of disease alteration, enabling detection of disease progression or treatment response,”…

About 41% of pulmonary arterial hypertension (PAH) patients in a multinational survey were initially misdiagnosed, seeing an average of 2.9 physicians before getting their correct diagnosis. The non-specific nature of their disease symptoms and a lack of awareness among patients and primary care physicians contribute to this delay,…

An algorithm based on artificial intelligence (AI) and machine learning may help in diagnosing pulmonary hypertension (PH), a new study shows. Its findings are particularly important for people suspected of having PH but whose disease remains uncertain using echocardiography, a noninvasive imaging method to examine heart structure and function.

Aria CV’s second-generation medical device for treating people with pulmonary arterial hypertension (PAH) — a balloon system known as the Gen 2 — has been successfully implanted in the first patient taking part in a U.S. study, according to a company press release. The…

A research project to help shed light about why people with the human immunodeficiency virus (HIV) are at higher risk for developing pulmonary hypertension (PH) was awarded a $2.67 million grant. The four-year grant from the National Heart, Lung and Blood Institute, part of the…

Sensydia announced that it successfully completed a fifth study of its investigative Cardiac Performance System (CPS), intended to more easily and quickly detect pulmonary hypertension (PH) and heart failure than current approaches. CPS is a handheld and noninvasive device, powered by artificial intelligence, that uses heart sound…

Four microRNAs (miRNAs) — small RNA molecules that regulate protein production — were found at different levels in blood samples from people with pulmonary hypertension (PH) compared with healthy people, a small study reported. Levels of two of these miRNAs were significantly higher in the PH patients versus the…

In people with pulmonary arterial hypertension (PAH), treatment with the novel cell therapy CAP-1002 was safe and showed encouraging efficacy, according to the results of a Phase 1a/b clinical trial. In particular, exploratory efficacy measures supported the potential of CAP-1002 in improving cardiopulmonary function, including exercise capacity, in PAH…

INOmax EVOLV DS, a device to deliver nitric oxide gas by inhalation to newborns with pulmonary hypertension (PH), is expected to be available in hospitals in the U.S. in the first half of 2024. The U.S. Food and Drug Administration (FDA) has cleared the next-generation device, developed by…

The noninvasive CPET test — known in full as cardiopulmonary exercise testing, which determines how the heart responds to exercise — may help to identify pulmonary arterial hypertension (PAH) patients at higher risk of clinical worsening, according to a new study in the U.S. The presence of heart rhythm…